• Room 06.019 - Medical Biology Centre

    United Kingdom

Accepting PhD Students

PhD projects

Open to PhD applications in the field of cancer research, cancer pharmacology, chemoresistance, cell and molecular biology, transcriptomics, biomarker development and drug discovery. Applications should meet the University's English language requirements, secured a source of funding, and who wish to pursue a research project in a relevant research topic. Exemplar PhD projects are detailed below: Mechanism of Drug activity in cancer https://www.dropbox.com/s/1r3f337i5m6mh32/PhD%20Studentship_HDAC6.pdf?dl=0 Molecular Pharmacology of GPCRs https://www.dropbox.com/s/04vjtc24i8svt3k/PhD%20Studentship_Neropeptide_galin.pdf?dl=0

20002019
If you made any changes in Pure these will be visible here soon.

Personal profile

Interests

Receptor Pharmacology

Cancer Pharmacology

Mechanmis of Drug action

Cell Signalling

microRNA

Methylated RNA Biomarkers

Cancer Biology

Ovarian Cancer

Research Statement

I am a University College Dublin Graduate and joined the School of Pharmacy, QUB, as a Lecturer in Pharmacology and cancer researcher in 2012.  Prior to joining QUB, I was a recipient of the Irish Cancer Society career development research fellowship in which I developed novel research on the role of the miR-433 microRNA as a biomarker of chemoresistance in ovarian cancer.  My research focus is on cancer pharmacology and stratified biomarker development and I primarily research the mechanism of action of anti-neoplastic agents.  Current projects include dissecting the molecular pharmacology of the histone deacetylase 6 (HDAC6) protein and the RNA demethylase enzymes.  New and emerging research from my group is focused on developing methods to detect methylated microRNA as next generation biomarkers of disease.  Areas of expertise include elucidating the mechanism of drug actions and downstream protein signalling in cell models of disease, cancer research and chemoresistance, cell and molecular biology, biomarker development and profiling microRNA in cells, tissue and plasma. My most significant research publications include studies of the miR-433 microRNA in chemoresistant ovarian cancer, IHC biomarker analyses and meta-analyse of the MAD2 protein in ovarian cancer prognosis.  Research from my group has been funded by the Irish Cancer Society, the Health Research Board of Ireland, BBSRC and MRC.

Fingerprint Dive into the research topics where Fiona Furlong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 29 Similar Profiles
Ovarian Neoplasms Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Protein Deficiency Medicine & Life Sciences
Cell Aging Medicine & Life Sciences
M Phase Cell Cycle Checkpoints Medicine & Life Sciences
Connective Tissue Growth Factor Medicine & Life Sciences
MicroRNAs Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2015 2019

Research Output 2000 2019

3 Citations (Scopus)
51 Downloads (Pure)

FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4

McClements, L., Annett, S., Yakkundi, A., O'Rourke, M., Valentine, A., Moustafa, N., Alqudah, A., Simões, B. M., Furlong, F., Short, A., McIntosh, S. A., McCarthy, H. O., Clarke, R. B. & Robson, T., 11 Apr 2019, In : BMC Cancer. 19, 351.

Research output: Contribution to journalArticle

Open Access
File
Neoplastic Stem Cells
Down-Regulation
Breast Neoplasms
Neoplasm Metastasis
Peptides

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

Annett, S., Moore, G., Short, A., Marshall, A., McCrudden, C., Yakkundi, A., Das, S., McCluggage, W. G., Nelson, L., Harley, I., Moustafa, N., Kennedy, C. J., deFazio, A., Brand, A., Sharma, R., Brennan, D., O'Toole, S., O'Leary, J., Bates, M., O'Riain, C. & 6 others, O'Connor, D., Furlong, F., McCarthy, H., Kissenpfennig, A., McClements, L. & Robson, T., 27 Nov 2019, In : British Journal of Cancer.

Research output: Contribution to journalArticle

Neoplastic Stem Cells
Ovarian Neoplasms
Peptides
Neoplasms
Heterografts

Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer

Bates, M., Furlong, F., Gallagher, M. F., Spillane, C. D., McCann, A., O'Toole, S. & O'Leary, J. J., 05 Oct 2019, In : Cancer Letters. 469, p. 11-21 11 p.

Research output: Contribution to journalArticle

M Phase Cell Cycle Checkpoints
Kinetochores
Anaphase
Chromatids
Neoplasms
2 Citations (Scopus)
160 Downloads (Pure)

BRCA1 and MAD2 are Co-expressed and are Prognostic Indicators in Tubo-ovarian High-grade Serous Carcinoma

Byrne, T., Nelson, L., Beirne, J., Sharpe, D., Quinn, J. E., Glenn McCluggage, W., Robson, T. & Furlong, F., 01 Mar 2018, In : International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 28, 3, p. 472-478

Research output: Contribution to journalArticle

Open Access
File
Protein Deficiency
Carcinoma
Survival Analysis
Survival
Paraffin

Selective HDAC6 inhibition with ACY-1215 promoted resistance to paclitaxel in epithelial ovarian cancer

Karolina Weiner-Gorzel, Tara Byrne, Alo McGoldrick, Caitlin Beggan, Nazia Faheem, Paula Cunnea, Eugene Dempsey, Sharon O'Toole, John O'Learry, Elaine Kay, Tracy Robson, Amanda McCann& Fiona Furlong, 22 Feb 2018, p. 32. 33 p.

Research output: Contribution to conferenceAbstract

Prizes

Mesangial Cells
Diabetic Nephropathies
Actin Cytoskeleton
Transforming Growth Factor beta
Research

Downregulation of MAD2 renders cancer cells resistant to Paclitaxel

Fiona Furlong (Recipient), 2008

Prize: Prize (including medals and awards)

Paclitaxel
Down-Regulation
Research
Neoplasms
M Phase Cell Cycle Checkpoints
Paclitaxel
MicroRNAs
Ovarian Neoplasms
Cell Cycle

Predicting chemo-response in serous papillary epithelial ovarian cancer (EOC)

Fiona Furlong (Recipient), 2011

Prize: Prize (including medals and awards)

Ovarian epithelial cancer
Triple Negative Breast Neoplasms
Drug Therapy
Research

Activities 2010 2018

Selective HDAC6 Inhibition with ACY-1215 promoted resistance to paclitaxel in epithelial ovarian cancer

Fiona Furlong (Invited speaker)
22 Feb 2018

Activity: Talk or presentation typesInvited talk

Cancer Trials Ireland Scientific and Education Meeting

Fiona Furlong (Participant)
20 Oct 2017

Activity: Participating in or organising an event typesParticipation in workshop, seminar, course

Cancer Medicine (Journal)

Fiona Furlong (Peer reviewer)
2017

Activity: Publication peer-review and editorial work typesPublication peer-review

10th International Symposium on Translational Research in Oncology

Fiona Furlong (Participant)
28 Sep 201730 Sep 2017

Activity: Participating in or organising an event typesParticipation in conference

Sentinus Young Innovators The Big Bang Fair

Fiona Furlong (Advisor)
12 Jun 2017

Activity: Participating in or organising an event typesParticipation in Festival/Exhibition